



FORMULATION AND EVALUATION OF PARENTERAL METHOTREXATE NANOLIPOSOMES 
Original Article 
 
SHABNAMa PRATHIMA SRINIVAS*, D. S. RAVINDRA BABU, ,
Sri Venkateshwara College of Pharmacy (O. U), Hyderabad, Andhra Pradesh, India
b 
a*, Celon laboratories Limitedb, Hyderabad, Telangana, India 
Received: 12 Sep 2014 Revised and Accepted: 10 Oct 2014 
Email: drpssvcp@gmail.com  
ABSTRACT  
Objective: The objective of the present study was to encapsulate Methotrexate in liposomal formulation for treatment of cancer. Conventional 
compositions of Methotrexate are available but in high doses showvariation in bioavailability and they are associated with a number of toxicities 
when administered orally. To overcome these problems, in the present study, inclusion of Methotrexate in parenteral liposomal formulation was 
approached with the aim of increasing retention time at the site of action which leads to improvement in bioavailabilityand better tumor targeting. 
Methods: In this study, PEGylated Methotrexate liposomes containing Hydrogenated Soy Phosphatidyl Choline and Cholesterol were prepared by 
thin film hydration method. The main advantage of PEGylated lipid vesicles lies in the possibility of active-targeted delivery of drugs to the tissues 
or organs that need those most. Attempts were made to enhance the encapsulation by use of non-ionic surfactants such as Tween-80, Tween-20 and 
solubilityenhancers such as β-cyclodextrin. The characterization of formulated liposomes was carried out by vesicle size, zeta potential, %free drug 
and in-vitro dissolution.  
Results: Formulation containing 10mg/ml of Tween-20 and 20 mg/ml of β-cyclodextrin showed highest encapsulation efficiency. The optimized 
formulation has exhibited more than 90% release of the drug within a period of 4 days. The accelerated stability studies (40±2°C/ 75±5% RH) of the 
Methotrexate liposome were conducted for a period of three months and the formulation was found to be stable.  
Conclusion: These results suggest that the liposome encapsulated MTX may serve as a useful targeted drug delivery system for effective 
management of neoplastic diseases. 
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INTRODUCTION 
Phospholipid vesicles (liposomes) were originally developed as a 
model membrane system. However, it was soon realized that their 
capacity to entrap ions and small and large molecules along with 
their low permeability presented considerable advantages as a drug 
delivery system. The idea was that drugs entrapped in the aqueous 
space(s) inside liposomes could be delivered to the site of action 
with greater selectivity and/or less degradation than for the free 
drug. Their ability to potentiate the pharmacological efficacy of 
various drugs In vitro against mammalian cultured cells enhanced 
their prospects as a drug delivery system. The goal of any drug 
delivery system is to provide a therapeutic amount of the drug to the 
proper site in the body, to achieve prompt effect and then maintain 
the desired drug concentration. Liposomes are microscopic, fluid-
filled pouches, whose walls are made up of layers of phospholipids 
identical to the phospholipids that make up cell membrane [1]. 
The potential of liposomes for delivering anticancer drugs has been 
investigated extensively in different cancer types. Especially the 
chemotherapeutic drug doxorubicin has received much attention, 
since it is easy to load high amount of this drug into liposomes [2]. In 
fact, commercially available untargeted liposomes loaded with 
doxorubicin, marketed under the name Caelyx®, have already been 
approved for clinical use in several cancers [3] and have also been 
investigated in clinical trials for glioblastoma multiforme [4]. 
Untargeted liposomal formulations of doxorubicin benefits 
especially from the improved toxicity profile and have also 
demonstrated some improvements in therapeutic efficacy compared 
to the free drug [5]. So far, targeted liposomes have only been 
investigated in animal models of human cancers, where targeting of 
liposomal drugs to the cancer cells or the tumor vasculature have 
demonstrated a more pronounced inhibition of tumor growth than 
administration of free drug or untargeted liposomes [6]. Some 
recent publications employ a combination of several liposome types 
or conjugate a number of different targeting molecules to the surface 
of a single liposome, in order to achieve a more efficient tumor 
targeting than with only one targeting agent. Several of these studies 
indeed demonstrated a synergistic effect compared to only using 
one targeting agent [7, 8]. 
Methotrexate (MTX) is widely used in the treatment of neoplastic 
disorders. Methotrexate inhibits dihydrofolic acid reductase. 
Dihydrofolates must be reduced to tetrahyrofolates by this enzyme 
before they be utilized as carriers of one-carbon groups in the 
synthesis of purine nucleotides and thymidylate. Therefore, 
methotrexate interferes with DNA synthesis, repair, and cellular 
replication. The drug side-effect profile includes mouth sores, 
stomach upset, and low white blood counts. MTX can cause severe 
toxicity of the liver, kidneys, and bone marrow, which requires 
regular monitoring with blood tests. It can cause headache and 
drowsiness, itching, skin rash, dizziness, and hair loss. MTX when 
given orally has a short elimination half-life. In leukemic pediatric 
patients, oral absorption of methotrexate appears to be dose 
dependent and has been reported to vary widely (23% to 95%). The 
absorption of doses greater than 40 mg/m2
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 has been reported to be 
significantly less than that of lower doses. Food has been shown to 
delay absorption and reduce peak concentration. This can be 
overcome by encapsulating MTX in lipid vesicles with the aim of 
increasing the retention time at the site of action. PEGylated vesicles 
of MTX can be prepared which are “stealth” lipid vesicles that evade 
detection and destruction by phagocytes by virtue of the presence of 
hydrated PEG (polyethylene glycol) molecules. The other main 
advantage of PEGylated lipid vesicles lies in the possibility of active-
targeted delivery of drugs to the tissues or organs that need them 
most. Not only does this maximize delivery efficiency for the agent in 
question, but it also minimizes the chances of toxicity to other 
organs [9]. 
Materials 
Methotrexate was obtained from Fermion-Finland; Hydrogenated 
Soy Phosphatidyl Choline (HSPC), mPEG2000-Distearyl Phosphatidyl 
Ethanolamine and Cholesterol were obtained from Lipoid AG, 
Germany. β-cyclodextrin was obtained from Cydex pharmaceuticals. 
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Tween-20 and Tween-80 were obtained from Croda Inc. New Jersey. 
All other chemicals used were of analytical grade. 
Construction of calibration curve by UV 
A stock solution of (100mg/ml) standard drug was prepared, 
required dilutions were made with phosphate buffer pH 7.4. To a 
series of 10 mL volumetric flasks aliquots standard solutions were 
added and the volume was made up using phosphate buffer pH 7.4. 
The absorbance of these solutions was measured at 303 nm using 1 
cm quartz cuvette in UV-Visible double beam spectrophotometer.  
Preparation of liposomes 
Lipid nano vesicles were prepared by the thin-film hydration 
method using passive-loadingtechnique [10]. The molar ratios of 
lipids (phospholipids-mPEG-DSPE/HSPC and cholesterol) were 
accurately weighed and dissolved in a minimal quantity of a mixture 
of chloroform: methanol (2:1) in a 250 mL round bottom flask with a 
ground glass neck to obtain a clear solution. The solvent removal 
was achieved by using Buchi Rota evaporator rotated at 60 rpm in 
order to completely evaporate the solvent and to obtain a thin dry 
lipid film. Hydration of the dry lipid film was achieved by adding the 
MTX in PBS pH 7.4 buffer at a concentration of 1.5 mg/mL and the 
temperature of the hydrating medium was maintained above the 
gel-liquid crystal transition temperature (Tm) of the phospholipids 
with the highest Tm, before adding to the dry lipid. Once stable 
multilamellar vesicles (MLV) suspension was produced, it was 
subjected to sonication for a period of 20 minutes by transferring 
the suspension into a glass vial. 
In-process Checks 
RPM: 60rpm (film formation), 100rpm (Hydration). 
Temperature: 45°C (film formation), 60°C(Hydration). 
Physical characterization of liposomes 
Particle size and Zeta potential determination 
Determination of particle size (in nanometers) and size distribution 
(as the PDI) of the liposomal suspension was measured by using 
Horiba, Nanoparticle SZ-100 series. Zeta potential measurement of 
the optimized liposomal suspension was done by using the Malvern 
nano zeta sizer instrument. 
% Drug entrapment efficiency (EE) 
Encapsulation efficiency was determined as the percentage of 
methotrexate encapsulated in liposome to the original amount of 
Methotrexate added. To determine drug loading efficiency of 
liposome, lipid vesicles were lysed using methanol: ethanol (2:1). 
Entrapped %, free drug % were calculated by using the equations… 
Entrapment % = (Total Drug-Free Drug)/Total Drug*100 
            = (A2-A1)/A2*100 
Free Drug % = (Total Drug-Entrapment %) 
In vitro drug release  
The In vitro release of drug from the liposomal formulation was 
carried out by using membrane diffusion technique using the 
dialysis membrane. 5 ml of liposomal suspension containing known 
amount of drug was placed in a dialysis membrane previously 
soaked overnight. A glass cylinder open at both ends was placed in 
200 ml of PBS (pH 7.4), maintained at 370
Release kinetics 
C and stirred with the help 
of a magnetic stirrer. Aliquots (5 ml) of release medium were 
withdrawn at different time intervals and the sample was replaced 
with fresh PBS (pH 7.4) to maintain constant volume. The samples 
were filtered through 0.45μm membrane filter and were analyzed by 
UV spectrophotometry at a λ max of 303 nm.  
To analyze the In vitro release data various kinetic models were used to 
describe the release kinetics. The zero order rate equation (At = A0 – 
K0t) describes the systems where the drug release rate is independent of 
its concentration. The first order equation (Log C = log C0 – Kt / 2.303) 
describes the release from system where release rate is concentration 
dependent. Higuchi described the release of drugs from insoluble matrix 
as a square root of time dependent process based on Fickian diffusion. 
Mechanism of drug release from the liposomal solution is described by 
Korsmeyer equation / Peppas model [11]. 
Accelerated Stability Studies 
The accelerated stability study was conducted to monitor physical 
and chemical stability of the liquid form of parenteral Methotrexate 
liposomal formulation for up to three months. The stability 
parameters, such as description, pH and assay were determined as 
function of the storage time.  
RESULTS AND DISCUSSIONS 
Calibration curve of Methotrexate in UV spectrophotometer 
The UV absorbance of Methotrexate standard solution in the range 
of 2-20 µg/ ml of drug in buffer, pH 7.4 showed linearity at λ max 
303 nm. The linearity was plotted for absorbance against 
concentration with the slope equation y = 0.055x - 0.014. The 
standard curve is shown in Fig 1. 
 
 
Fig. 1: Standard graph of Methotrexate in phosphate buffer of pH 7.4Fourier Transformer Infra Red (FT – IR) Spectroscopy 
 
The compatibility between the drug and the selected lipid and 
other excipients was evaluated using FT-IR peak matching 
method. There was no appearance or disappearance of peaks in 
the drug-lipid mixture, which confirmed the absence of any 
chemical interaction between the drug, lipid and other chemicals 
as shown in Fig 2 and 3. 
Preparation of Methotrexate liposomal formulation 
The Liposomes were prepared by dried thin film hydration 
technique using rotary evaporator. The parenteral liposomal 
formulation containing Methotrexate was prepared by using lipids, 
cholesterol and non-ionic surfactants- Tween-20 and Tween-80 and 
β-cyclodextrin was used as a solubility enhancer and all other 
parameters like temperature and RPM were kept constant. Drug to 
lipid ratio was varied and for optimized formulation it was found to 
be 1:20. The composition of the formulations is shown in table 1.  
Among compositions four formulations, namely F7, F9, F10 & F12 
were selected as optimized batches for further evaluation as shown 
in table 2. 
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Fig. 2: FTIR of Methotrexate (Pure API) 
 
 
Fig. 3: FTIR of Methotrexate liposomal formulation 
 
Table 1: Formulation studies of Methotrexate liposomes 
S. No. Ingredient Qty/ml 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 
1.  Methotrexate (mg) 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
2.  Hydrogenated Soy Phosphatidyl Choline (mg) 30 30 40 50 50 50 50 50 50 50 50 50 50 
3.  mPEG2000-DSPE (mg) 8 8 8 8 8 8 8 8 8 8 8 8 8 
4.  Cholesterol (mg) 8 18 18 18 24 36 50 50 50 50 50 50 50 
5.  Tween-80 (mg) - - - - - - - 5 10 - - - - 
6.  Tween-20 (mg) - - - - - - - - - 10 10 10 10 
7.  β-Cyclodextrin (mg) - - - - - - - - - - 10 20 30 
8.  Phosphate buffer (7.4) q. s q. s q. s q. s q. s q. s q. s q. s q. s q. s q. s q. s q. s 
 
Table 2: Optimized Formulations of Methotrexate liposomes 
S. No. Ingredient Qty/ml 
F7 F9 F10 F12 
1 Methotrexate(mg) 1.5 1.5 1.5 1.5 
2 HSPC(mg) 50 50 50 50 
3 mPEG2000-DSPE(mg) 8 8 8 8 
5 Cholesterol(mg) 50 50 50 50 
5 Tween-80(mg) - 10 - - 
6 Tween-20(mg) - - 10 10 
7 β-Cyclodextrin(mg) - - - 20 
8 Phosphate buffer (7.4) q. s q. s q. s q. s 
9 Molar ratio of Drug/Lipid 1:20 1:20 1:20 1:20 
10 Molar ratio of Lipid/Cholesterol 1:1 1:1 1:1 1:1 
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Fig. 4: Particle size distribution of formulated Methotrexate liposomes 
 
 
Fig. 5: Zeta Potential of Formulated Methotrexate liposomesEntrapment efficiency of Methotrexate in liposomes 
 
 
Fig. 6: Graphical representation of Encapsulation efficiency of formulated Methotrexate liposomes 
 
Characterization particle size analysis 
Particle size analysis of the sonicated lipid vesicles was determined 
using Horiba, Nanoparticle SZ-100 series. The results are in Fig. 4. It 
was observed that the average particle size was found to be 44.5 nm 
for optimized formulation and PDI (poly dispersity index) was found 
to be 0.393 indicating good dispersion of uniformly sized lipid vesicles. 
Zeta potential analysis 
The zeta potential value of liposomal solution F12 was found to be -
41.6which lie near to the arbitrary value indicating good stability 
and the negative value indicates no agglomeration of particles. The 
results are represented in Fig. 5. 
The drug entrapment efficiency studies were conducted for various 
formulations. The entrapment efficiency of all formulations is 
graphically represented in Fig. 6. The formulation F12 showed 
maximum entrapment efficiency.  
In vitro dissolution data 
The In vitro dissolution profile of optimized formulations was 
determined by membrane diffusion method. The dissolution was 
carried out for a period of 96 hrs in 7.4 pH phosphate buffer. The 
cumulative percent release of optimized formulations at various 
time intervals was calculated. In optimized formulations sustained 
release was observed up to 96 hrs. These results indicate slow 
release and more encapsulation of the drug. 
Release Kinetics 
The release kinetics of F7, F9, F10 and F12 formulations was 
studied. It was observed that the total drug present in the 
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formulated liposomes was released in 96 hrs. The regression co-
efficient and diffusion co-efficient values for four optimized 
formulations are tabulated in table 3. Plots of zero order, first order, 
Higuchi and Peppasare depicted in Fig. 7-10. These values are 
compared with each other for model and drug equation. Based on 
highest regression [r2
 
] values, the best-fit model for optimized 
formulations was found to be zero order release in case of F12and 
the formulations F7, F9, and F10 followed higuchi diffusion model. 
All the formulations were then fitted into korsmeyer-peppas model 
and n values are reported in table 3. For all the optimized 
formulations, the ‘n’ value was in the range of 0.85-0.9 indicating 
case-II transport. 
  
Fig. 7: Zero order release graph for 
optimized formulations F7, F9, F10 & F12 
 
Fig. 8: First order release graph for 
optimized formulations F7, F9, F10 & F12  
 
  
Fig. 9: Higuchi release graph for optimized 
formulations F7, F9, F10 & F12optimized 
Fig. 10: Korsemeyer Peppas release graph for 
formulations F7, F9, F10 & F12 
 
Table 3: Regression coefficient and diffusion coefficient values 
Formulation 
 
Zero Order First order Higuchi Korsemeyer 
R K2 R0 K2 R1 K2 RH n 2 
F7 0.917 0.997 0.925 0.0007 0.981 10.52 0.910 0.856 
F9 0.930 1.023 0.937 0.0007 0.979 10.70 0.941 0.895 
F10 0.968 0.980 0.972 0.0006 0.973 10.02 0.940 0.889 
F12 0.974 0.961 0.968 0.0007 0.889 9.359 0.973 0.889 
 
Table 4: Results of Stability testing of Methotrexate liposomal formulation 
Time point F12 
Initial 1 month 2 months 3 months 
Description Yellow coloredcake Yellow colored cake Yellow colored cake Yellow colored 
cake 
Ph 6.91 7.02 7.02 7.11 
Assay 80.22% 78.53 % 77.12% 77.12% 
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Stability studies 
The stability of Methotrexate liposomes was evaluated for optimized 
formulation F12 after storage at accelerated condition at 
400C±200
1. Noveen Konda, Arvind G, Sumit Shah, Prashanth P. Formulation 
and evaluation of non-pegylated doxorubicin liposomal drug 
delivery system. Int J Pharm Sci 2013;5:541-7. 
C/75%±5% RH for 3 months. The description, pH, and 
assay of the sample was determined as a function of the storage 
time. The liposomes stored at accelerated condition were found to 
be stable for duration of 3 months. The results are shown in table 4. 
CONCLUSION 
The parenteral liposomal formulations containing Methotrexate can be 
successfully formulated by thin film hydration method using passive 
loading technique. Improvement in encapsulation efficiency and 
sustained release was achieved by increasing the concentration of lipids, 
non-ionic surfactants Tween-80, Tween-20 and solubility enhancing 
agents – β-cyclodextrin. From the above study it is concluded that 
parenteral liposomal formulations of Methotrexate can be explored as a 
potential candidate for treatment of various neoplasticdiseases. 
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